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EMQN best practice guidelines for the laboratory
diagnosis of osteogenesis imperfecta
Fleur S van Dijk1, Peter H Byers2, Raymond Dalgleish3, Fransiska Malfait4, Alessandra Maugeri1,
Marianne Rohrbach5, Soﬁe Symoens4, Erik A Sistermans1 and Gerard Pals*,1
Osteogenesis imperfecta (OI) comprises a group of inherited disorders characterized by bone fragility and increased
susceptibility to fractures. Historically, the laboratory conﬁrmation of the diagnosis OI rested on cultured dermal ﬁbroblasts to
identify decreased or abnormal production of abnormal type I (pro)collagen molecules, measured by gel electrophoresis. With the
discovery of COL1A1 and COL1A2 gene variants as a cause of OI, sequence analysis of these genes was added to the diagnostic
process. Nowadays, OI is known to be genetically heterogeneous. About 90% of individuals with OI are heterozygous for
causative variants in the COL1A1 and COL1A2 genes. The majority of remaining affected individuals have recessively inherited
forms of OI with the causative variants in the more recently discovered genes CRTAP, FKBP10, LEPRE1,PLOD2, PPIB,
SERPINF1, SERPINH1 and SP7, or in other yet undiscovered genes. These advances in the molecular genetic diagnosis of OI
prompted us to develop new guidelines for molecular testing and reporting of results in which we take into account that testing
is also used to ‘exclude’ OI when there is suspicion of non-accidental injury. Diagnostic ﬂow, methods and reporting scenarios
were discussed during an international workshop with 17 clinicians and scientists from 11 countries and converged in these
best practice guidelines for the laboratory diagnosis of OI.
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INTRODUCTION
Classiﬁcation of osteogenesis imperfecta
Osteogenesis imperfecta (OI) comprises a heterogeneous group of
disorders characterized by susceptibility to bone fractures with severity
that ranges from death in the perinatal period to subtle increase in
fracture frequency and in almost all cases presumed or proven defects
in type I (pro)collagen biosynthesis.1 In 1979, David Sillence devel-
oped a four-type classiﬁcation, which is still in use for classiﬁcation
according to clinical/radiological features: OI type I (mild OI with
bone fragility and blue sclerae), II (perinatal lethal), III (progressive
deforming) and IV (normal sclerae and mild deformity).2,3 Dominant
COL1A1/2 variants appeared to be causative in the majority of OI
types. In 2004, OI types V and VI were added to this classiﬁcation
because of speciﬁc clinical/radiological and/or histological features,
absence of abnormalities of type I (pro)collagen synthesis or structure
on gel electrophoresis and absence of causative variants in the
COL1A1/2 genes.4,5 With the discovery of rare recessive genetic causes
of OI (see Table 1), it was proposed to extend the classiﬁcation with
OI types VII and VIII.6 However, the classiﬁcation and subdivision
into different types of OI is still under discussion1 because the
phenotypic spectrum that results from mutations in some of these
genes is almost as broad as that with mutations in type I collagen
genes. There is also debate as to whether Bruck syndrome type I7
and II,8 characterized clinically by bone fragility and congenital
contractures of the large joints, should be classiﬁed as a type of OI.
Biosynthesis of type I collagen
Most individuals affected with OI are heterozygous for a causative
variant in either of the two genes, COL1A1 or COL1A2, which encode
the proa1(I) and proa2(I) chains of type I procollagen, respectively.
Type I collagen is the major structural protein in bone, tendon and
ligament. Recently, rare recessive genetic causes of OI have been
described and, in all but one, the identiﬁed genes encode proteins
involved in the biosynthesis of type I procollagen (Figure 1, Tables 1
and 2).9,10
Genes, proteins and causative variants
Autosomal dominant OI. The most common form of OI in most
populations is OI type I. Cultured dermal ﬁbroblasts from affected
individuals produce about half the normal amount of type I procolla-
gen molecules, which have normal structure. OI type I usually
results from variants in one COL1A1 allele (frameshift, nonsense
and splice-site alterations) that lead to mRNA instability and hap-
loinsufﬁciency. In a small subset of individuals with OI type I,
substitutions for glycine by small amino acids (cysteine, alanine and
serine) near the amino terminal ends of the triple-helical domains of
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www.nature.com/ejhgeither COL1A1 or COL1A2 are found. In contrast, OI types II–IV
are usually caused by sequence variants in either COL1A1 or COL1A2
that result in substitutions for glycine residues in the uninterrupted
Gly-X-Y triplet repeat of the 1014-residue triple-helical domains
encoded by each gene. Less common causative variants include
splice-site alterations, variants in the carboxyl-terminal propeptide
Table 1 Genes in which sequence variants cause OI
Gene
OMIM
(Gene)
RefSeqGene
genomic
reference RefSeq mRNA reference RefSeq protein reference
Locus reference
genomic (LRG)
COL1A1 120150 NG_007400.1 NM_000088.3 NP_000079.2 LRG_1
COL1A2 120160 NG_007405.1 NM_000089.3 NP_000080.2 LRG_2
CRTAP 605497 NG_008122.1 NM_006371.4 NP_006362.1 LRG_4
FKBP10 607063 NG_015860.1 NM_021939.3 NP_068758.3 LRG_12
LEPRE1 610339 NG_008123.1 NM_022356.3 (transcript variant 1) NP_071751.3 (isoform 1, P3H1a, long) LRG_5
NM_001146289.1 (transcript variant 2) NP_001139761.1 (isoform 2, P3H1b, short)
PLOD2 601865 NG_009251.1 NM_182943.2 (transcript variant 1) NP_891988.1 (isoform 1, LH2b, long) —a
NM_000935.2 (transcript variant 2) NP_000926.2 (isoform 2, LH2a, short)
PPIB 123841 NG_012979.1 NM_000942.4 NP_000933.1 LRG_10
SERPINF1 172860 NG_028180.1 NM_002615.5 NP_002606.3 —a
SERPINH1 600943 NG_012052.1 NM_001235.2 NP_001226.2 —a
SP7 606633 NG_023391.1 NM_001173467.1 (transcript variant 1) NP_001166938.1b —a
NM_152860.1 (transcript variant 2) NP_690599.1b
aLRG sequences have been developed to provide a stable genomic reference for each gene region annotated with transcripts, proteins and other associated data.44 For some recently discovered
genes in which sequence variation causes OI, no LRG is available yet.
bThe two transcripts of the SP7 gene are translated into identical proteins.
Figure 1 Critical steps in collagen type I biosynthesis and indication of genes known to be involved in OI. Type I collagen is the major structural protein in
bone, tendon and ligament. It is ﬁrst synthesized in the rough endoplasmic reticulum (rER) as type I procollagen, containing C- and N-terminal propeptides.
In the rER, the two a1(I)-collagen chains encoded by COL1A1 and the one a2(I)-collagen chain encoded by COL1A2 comprising predominantly Gly-X-Y
triplets, align and assemble in the C- to-N direction to form a triple helix. During folding, collagen is modiﬁed by, among others, speciﬁc enzymes that
hydroxylate lysine and proline residues and glycosylate hydroxylysyl residues. This process is called post-translational modiﬁcation and it stops when triple
helix assembly is complete. The CRTAP/P3H1/CyPB complex encoded by the CRTAP, LEPRE1 and PPIB genes, is responsible for the 3-hydroxylation of
P986 (p.P1164 counting from the methionine that initiates translation) but will most likely also act as a cis-trans isomerase and a molecular chaperone.
FKBP65 encoded by FKBP10 also acts as a molecular chaperone for type I procollagen. The protein product of PLOD2 (procollagen-lysine, 2-oxoglutarate
5-dioxygenase 2) hydroxylates telopeptide lysines in the rER. HSP47 encoded by SERPINH1 is thought to maintain the stability of the triple helix. After
folding, the procollagen molecules are transported through the Golgi apparatus and plasma membrane (PM) into the extracellular matrix (ECM) where
cleavage of the N-and C-terminal propeptides occurs and collagen molecules aggregate to form ﬁbrils.
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sequence alterations. Most of these variants result in synthesis of
abnormal type I procollagen molecules characterized by post-transla-
tional over-modiﬁcation of the triple-helical domain, which results in
alterations visible by SDS-polyacrylamide gel electrophoresis. Loss of
expression of either gene because of large-scale deletions appears to be
rare.11–15 More than 1000 distinct variants in the COL1A1 and
COL1A2 genes have been identiﬁed that cause OI (R Dalgleish:
Osteogenesis Imperfecta Variant Database (https://oi.gene.le.ac.uk,
accessed 3 May 2011).16,17
Autosomal recessive OI including Bruck syndrome
In the last 5 years, candidate–gene approaches have identiﬁed several
loci in which causative variants have been identiﬁed which result in
the long-sought causes for recessively inherited forms of OI (see
Figure 1, Table 2). We classify these genes in four groups—(i) one
in which the genes encode proteins that contribute to the initial phase
of chain recognition and propagation of molecular folding (CRTAP,
LEPRE1 and PPIB)18–26 the second in which the genes encode proteins
involved in the ﬁnal quality control of type I procollagen (FKBP1027–29
and SERPINH130), the third, which involves a gene encoding proteins
involved in late modiﬁcation and crosslink formation (PLOD28,31)
and the fourth group, which involves recently recognized genes
encoding proteins involved in bone cell differentiation (SP732 and
possibly SERPINF133).
Reasons for referral
Prenatal. Prenatal ultrasounds showing abnormalities suggestive of
OI (diminished mineralization of skull, platyspondyly or bowing,
shortening and/or fractures of long bones) are an important reason for
referral for molecular diagnostics of OI.
Postnatal. Radiographs at birth suggestive of OI, recurrent and/or
unexplained fractures with or without suspicion of non-accidental
injury (NAI), primary (idiopathic) low bone mass, preferably with
exclusion of secondary causes, a family history of OI and request for
conﬁrmation of the clinical diagnosis are all reasons for referral for
molecular diagnostics of OI. However, in some cases dentinogenesis
imperfecta or even blue sclerae might be the only reason for referral.
As such, physicians from many specialties (gynaecologist, paediatri-
cian, orthopaedic surgeon, clinical geneticist, general practitioner,
dentist, ear nose throat specialist, endocrinologist, internist and
ophthalmologist) might refer a patient for molecular analysis.
Depending on the age of presentation, OI can be difﬁcult to distin-
guish from some other genetic conditions, for example, Ehlers–Danlos
syndrome arthrochalasis type (former EDS VIIA and B), isolated
Table 2 Characteristics of recessive OI-related genes
Gene Protein Protein function
Results of biochemical analysis in
case of causative variants OI type
CRTAP18–21,26 Cartilage-associated
protein (CRTAP)
CRTAP forms a complex with the proteins encoded by
LEPRE1 and PPIB. Apart from 3-prolyl hydroxylation activity,
the complex appears to have cis-trans isomerase activity and
is thought to act as a molecular chaperone initiating chain
recognition and helical folding.
Post-translational over-modiﬁcation
Decreased 3-prolyl hydroxylation of
P986 in the proa1(I)-collagen chainsa
I I ,I I I ,I V
FKBP10 27–29 FKBP65 FKBP65 has prolyl cis-trans isomerase activity, and can
bind collagen
No post-translational over-modiﬁcation III/Bruck syndrome
(bone fragility with
congenital
contractures
of large joints)
LEPRE118–22,23,26 Prolyl 3-hydroxylase 1
(P3H1)
P3H1 forms a complex with the proteins encoded by CRTAP
and PPIB. Apart from 3-prolyl hydroxylation activity, the
complex is thought to act as a molecular chaperone and a
cis-trans isomerase.
Post-translational over-modiﬁcation
Decreased 3-prolyl hydroxylation of
P986 in the proa1(I)-collagen chainsa
II, III
PLOD2 8,31 Lysyl hydroxylase 2 Telopeptide lysyl hydroxylase-2 modiﬁes lysyl residues in the
telopeptides of type I collagen involved in intermolecular
cross-link formation
Underhydroxylation of lysine residues
in collagen type I telopeptides resulting
in aberrant bone collagen type I cross
linking
Bruck syndrome
PPIB18,24–26 Cyclophilin B P3H1 forms a complex with the proteins encoded by
LEPRE1 and CRTAP Apart from 3-prolyl hydroxylation
activity, the complex is thought to act as a molecular
chaperone and a cis-trans isomerase
Post-translational over-modiﬁcation
in most cases
Decreased 3-prolyl hydroxylation of
P986 in the proa1(I)-collagen chains
in most casesa
I I ,I I I ,I V
SERPINF133 PEDF PEDF is known mainly for its strong inhibition of angiogen-
esis. However, expression analyses in bone tissue from
wild-type mice and in vitro experiments with murine cell
systems support a role for PEDF in bone formation and
remodelling
No post-translational over-modiﬁcation III
SERPINH130 HSP47 HSP47 monitors the integrity of the triple helix of the type I
procollagen at the ER/cis-Golgi boundary
No post-translational over-modiﬁcation III
SP732 Osterix Osterix is an osteoblast-speciﬁc transcription factor which
has been shown to be essential for bone formation in mice
No post-translational over-modiﬁcation IV
ap.Pro1164 counting from the methionine that initiates translation.
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sphatasia, and non-genetic causes of fractures including NAI and
idiopathic juvenile osteoporosis.2,34–36
Non-accidental injury. Many referrals for OI diagnostics occur in the
context of suspected NAI in an attempt to exclude a genetic cause of
fractures. Fractures resulting from NAI occur in 24 per 10000 children
under 3 years of age whereas the OI prevalence is 1 per 10000–
20000.34 The incidence of OI among children evaluated for NAI is
2–5%.34 Differentiation is aided by an experienced clinician and
radiologist familiar with OI36 as the nature and localization of
fractures in OI and NAI can often be distinguished.37 However,
because injuries may involve infants before many of the clinical
features of OI are apparent, laboratory diagnostics for OI can certainly
be helpful in this differentiation.
MATERIALS AND METHODS
A group of clinicians and scientists involved in OI diagnostics met on 28–29
June 2010 at a workshop in Amsterdam, the Netherlands, to formulate Best
Practice Guidelines for the molecular genetic diagnosis of OI supported by the
European Molecular Genetics Quality Network (EMQN).
RESULTS
Discussions focussed on diagnostic ﬂow, methodologies, inter-
pretation of results and reporting. Consensus guidelines were
established.
DISCUSSION
The diagnostic ﬂow
The ‘traditional’ way to establish or conﬁrm the diagnosis of OI is
based on studies of collagens synthesized by cultured dermal ﬁbro-
blasts. Previous studies35 demonstrated that either quantitative or
qualitative alterations can be identiﬁed in about 90%38 of individuals
with clinically conﬁrmed OI. Biochemical analysis will separate
individuals with quantitative defects (OI type I), from those with
qualitative defects (OI types II–IV) because of causative variants in the
COL1A1/2, CRTAP, LEPRE1, PPIB genes and those with no abnorm-
alities detected. Electrophoretic analysis of type I procollagen may also
identify other disorders that can mimic some aspects of OI: EDS
kyphoscoliotic type (type VIA), EDS arthrochalasia type (types VIIA
and VIIB) and EDS dermatosparaxis type (type VIIC).11 Also,
cultured ﬁbroblasts provides a resource for the analysis of RNA
splicing and unclassiﬁed variants. However, biochemical analysis will
not identify some quantitative defects of type I procollagen, certain
causative variants that alter sequences in some coding regions of the
COL1A1/COL1A2 genes and recessive forms of OI (including Bruck
syndrome) that result from variants in FKBP10, PLOD2, SERPINF1,
SERPINH1 or SP7. Furthermore, prenatal diagnosis by biochemical
analysis is only possible in chorionic villus cells and is effective with
qualitative alterations9 but unsuitable for quantitative defects and
delays time of diagnosis by 2–4 weeks compared with genetic analysis.
In contrast, direct genomic analysis (sequencing) of the known
genes should identify causative variants in 495% of affected indivi-
duals in most populations.39,40 Next generation sequencing has gained
importance in the laboratory diagnosis of OI – in part because of
shorter time to diagnosis and in part because of the added value of the
information as well as reduced costs, which is important for the
precise determination of recurrence risk (autosomal dominant versus
recessive), prenatal diagnosis and pre-implantation genetic diagnosis.
Given these considerations and current facilities, the consensus of
the EMQN Best Practice in OI meeting was to initiate laboratory-
based diagnostic studies with direct genomic sequencing of the type I
procollagen genes, COL1A1 and COL1A2.T h ea p p r o a c ht od i a g n o s i s
is detailed in Figure 2. It was agreed that the ‘traditional’ approach can
still be used in the context in which genomic DNA sequencing is
unavailable or the ﬁnancial barriers are high. Moreover, analysis of
proteins and mRNA/cDNA from cultured ﬁbroblasts remain valuable
tools for follow-up studies.
Explanation of diagnostic work ﬂow
Sequencing of all type I procollagen gene exons. Procollagen type I
gene sequencing should identify causative variants in 90% of affected
individuals,39,40 provided that the clinical diagnosis of OI is accurate.
In some cases a follow-up study is needed to determine whether a
variant is causative. This will often include genetic studies in the
parents with correlation to the phenotype observed in the parent, or
analysis of mRNA splicing and protein-based biochemical studies on
cultured dermal ﬁbroblasts.
If no causative variant in the COL1A1/2 genes is identiﬁed by
sequence analysis, the next step is to determine if a deletion or
duplication of some or all of the coding regions of either gene has
occurred. Strategies such as array-based analysis, MLPA or qPCR if
properly validated are considered equivalent by the working group in
their detection of such alterations. From currently available data in the
represented laboratories, the added causative variants expected from
this approach should be about 1–2%. In case of OI types II–IV, after
identifying the causative variant in the index patient, determination of
parental mosaicism by sequence analysis of DNA from blood from
each parent will provide data for genetic counselling with respect to
recurrence risk and care in subsequent pregnancies.
Re-review of clinical data and the question of NAI. When no causative
COL1A1/2 variant is found, clinical priorities should be re-considered.
Failure to ﬁnd a causative variant occurs if there is technical failure, or
if no causative variant is present in these genes (because of causative
variants in other (un)known genes or because the patient does not
have OI). Therefore, referring physicians should be encouraged to
provide a completed clinical checklist (Supplementary Table 1) and
X-rays of the patient. This clinical/radiological information should be
reviewed by a clinical geneticist or a clinician with experience in OI.
This can help to determine the likelihood of OI in the particular
patient. With clear evidence of OI, further analysis should proceed
(Figure 2).
However, if the primary reason for genetic study is to identify
children with OI among the larger group suspected for NAI, analysis
can reasonably stop after COL1A1/2 sequencing unless there is a
strong suggestion of consanguinity or recessive inheritance. Justiﬁca-
tion of this decision rests on the following considerations. First,
previous studies indicate that fewer than 5% of infants studied for
suspicion of NAI are found to have OI by biochemical or DNA-based
studies.34 Second, DNA-based analysis will identify a causative variant
in 490% of all individuals with OI39,40 so that the remaining risk that
an infant has OI, will be about 0.5%. Third, at present all infants
with recessive OI have obvious radiographic abnormalities ﬁtting a
diagnosis of OI and not of NAI.
Identiﬁcation and characterization of causative variants in autosomal
recessive OI. Variants in the genes causing recessive OI are estimated
to account for about 5 or 6% of individuals with OI. This represents
the pooled estimates from all the laboratories represented at the
workshop. Although laboratory context and clinical criteria may in
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genes at the same time to minimize turnaround time. If no, or only
one, causative variant is identiﬁed by sequence analysis, the next step
is to determine by array-based analysis, MLPA or qPCR if a deletion or
duplication of some or all of the coding regions of either allele has
occurred. Once recessive causative variants are identiﬁed, parental
conﬁrmation of carrier status should be completed, ﬁrst to conﬁrm
that the causative variants in the index case are inherited in trans and,
second, to exclude the possibility of uniparental disomy in the case of
homozygosity in the infant.
Analysis of proteins and mRNA/cDNA from cultured ﬁbroblasts
(functional analysis). By following the guidelines to this point,
virtually all causative variants in type I procollagen genes and in the
recessive OI-related genes will have been identiﬁed. However, in some
cases analysis of proteins and mRNA/cDNA from cultured ﬁbroblasts
can have an additive value. First of all, mRNA/cDNA analysis provides
a tool for studying the effect of unclassiﬁed variants suspected to alter
splicing. Moreover, this approach can unravel the effect of deep
intronic variants that alter the mRNA sequences usually by conversion
of cryptic exons to active exons and which would not be detected by
gDNA sequencing. In these cases, biochemical analysis of type I
procollagen chains can detect quantitative defects if the new exon
results in introduction of a premature stop codon and nonsense-
mediated mRNA decay, or qualitative defects if the mRNA is stable
and translated into an abnormal protein. When OI type I is suspected,
but genomic DNA sequencing is unavailable or too costly, COL1A1
null-allele14 testing on cDNA can be used to conﬁrm the diagnosis.
However, this approach relies on the availability of informative
markers and will not lead to the identiﬁcation of the disease-causing
variant.
Analysis of remaining samples. Some diagnostic laboratories main-
tain research arms and the identiﬁcation of the additional OI-related
genes has proﬁted from the repositories of cells and DNA samples
from individuals with OI because of unknown genetic causes. This
practice should continue and cells and DNA samples should be
banked for future analysis. If the diagnostic laboratory does not
maintain such a resource, banking with ones that do, should be
considered.
Laboratory diagnosis of OI
Molecular analysis for OI. Molecular analysis for OI includes sequen-
cing or mutation scanning and deletion/duplication testing for
COL1A1 and COL1A2, followed by sequencing of recessive OI-related
genes (see Table 1). Preferred material for testing is genomic DNA
from blood, but other sources can be used as well (see Tables 3a and b).
For general issues regarding sample labelling and identiﬁcation,
sequence analysis and interpretation see ‘Practice guidelines for Sanger
Sequencing Analysis and Interpretation’ (http://www.cmgs.org/BPGs/
pdfs%20current%20bpgs/Sequencingv2.pdf).
gDNA and cDNA sequencing
Current practices in sequencing of the type I collagen genes differ
among laboratories in that some use exon-by-exon ampliﬁcation
followed by sequence determination (Supplementary Appendix Tables
3A and B) and others use a multi-exon substrate for analysis. If
properly validated, both will provide the same mutation capture
probability and their use should be determined by local preferences.
To identify splice variants, primer sequences for PCR used for direct
sequencing should be designed far enough from intron–exon bound-
aries to allow reading of the branch sites, consensus splice donor and
acceptor sites or UTR sequences of acceptable quality. With regard to
sequence analysis of cDNA, large fragments should be analysed to
allow detection of multi-exon deletions, because these could be missed
when primers are located close to the exon junctions at multiple sites.
The analysis of cDNA from ﬁbroblasts is warranted when an unknown
variant is found that might affect splicing. In addition, cDNA
sequence analysis may detect null-alleles without a known cause (eg,
an unknown variant in the promoter region) if care is taken to analyse
regions in which coding sequence heterozygosity is known.
Report Causative variant
Sequence analysis and
quantitative
analysis of COL1A1 and
COL1A2 on genomic DNA
Confirmed causative
variant(s) or second
causative variant found
Segregation and
functional analysis
No causative variant
Re-evaluation of clinical
diagnosis OI
Non-confirmed
Non-confirmed
causative variant(s) or
no second causative
variant found
No
further
testing
needed
Confirmed
Analysis of recessive
genes
Report and banking
of samples
for research No causative variant
Figure 2 Preferred diagnostic ﬂow in OI. The approach to diagnosis is designed to maximize the likelihood that causative variants will be identiﬁed in all
affected individuals or assign those without causative variants to research pools. This ﬂow assumes that the clinical diagnosis of OI is well established
according to the traditional diagnostic criteria. With clear evidence of OI from radiological and clinical examination, further analysis should proceed
according to the proposed strategy. Functional analysis consists of analysis of proteins and mRNA/cDNA from cultured ﬁbroblasts and also includes COL1A1
null allele testing in certain selected cases.
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Quantitative analysis by MLPA (kits for COL1A1 and COL1A2 have
been designed by MRC-Holland, available at http://www.mlpa.com)
and qPCR is particularly important in cases without a detected
molecular cause in which only genomic DNA is available and without
heterozygous polymorphic variants detected by sequencing. Recently,
complete COL1A1 allele deletions have been reported to cause OI
type I.13 For reliable quantitative testing (MLPA/qPCR) patient and
control materials from the same source (eg, blood or ﬁbroblasts)
should be used for comparison and the same DNA puriﬁcation
protocol should be used for all samples within a test series.
Protein analysis. Protein analysis of type I (pro)collagen (Supple-
mentary Appendix Figures 3A–D) is used to detect quantitative and
qualitative changes. The method used for this analysis is based on in
vitro labelling of collagen in cultured ﬁbroblasts, followed by electro-
phoresis on 2 M urea SDS-PAGE gels (the 2 M urea enhances chain
separation) and autoradiography.41 The analysis of procollagens is
achieved by omitting the pepsin digestion step from the collagen
protocol. Procollagen electrophoresis enhances detection sensitivity of
quantitative type I (pro)collagen defects (OI type I), visualizes defects
in type I (pro)collagen located in the N-terminal region of the type I
collagen triple helix more clearly and distinguishes between EDS VIIC
and EDS VIIA and B (if samples are analysed after labelling in the
presence and absence of dextran sulphate to enhance proteolytic
processing).42
Prenatal diagnosis. Prenatal diagnosis is possible in case of identiﬁ-
cation of known disease-causing variant(s) both on genomic DNA
extracted from chorionic villus sample (CVS) cells and amniocytes.
‘Testing for Maternal Cell Contamination (MCC) in Prenatal Samples
for Molecular Studies’ (http://www.cmgs.org/BPGs/pdfs%20current%20
bpgs/MCC_08.pdf) should be applied. In those rare instances when
post-translational over-modiﬁcation of (pro)collagen type I is visible
in, for example, cells from an affected sibling but no disease-causing
variant(s) have been detected in the genes involved in OI, electro-
phoresis of type I (pro)collagen from cultured CVS cells can be used
for prenatal diagnosis. Amniocytes are good sources of DNA but they
do not make type I procollagen in sufﬁcient abundance to permit
prenatal diagnosis.
Interpretation of performed diagnostics
For the interpretation of an observed sequence variant it is essential to
establish the causal role of the variant in the pathogenesis of the
disease. Textboxes 1 and 2 include descriptions of variants in the genes
involved in OI that are likely to be pathogenic or that should be
considered as unclassiﬁed variants.
Reporting
General information on requirements for variant reporting can be
found in the OECD Guidelines for Quality Assurance in Molecular
Genetic Testing (http://www.OECD.org/dataoecd/43/6/38839788.pdf)
and in the guidelines issued by the Swiss Medical Genetics Society
(http://sgmg.ch/user_ﬁles/images/SGMG_Reporting_Guidelines.pdf).
Reporting scenarios
Finding a causative variant in the COL1A1/COL1A2 genes in an affected
index case. The report should state that a causative variant has been
detected and that this conﬁrms the clinical diagnosis. The report
should include a description of the reason why a particular variant is
considered causative. Determination of the parental origin of the
detected variant(s) should be advised. Testing of relatives at risk
should be offered in conjunction with appropriate counselling.
In the case of severe/lethal OI because of a causative variant in
COL1A1 or COL1A2, the measured recurrence risk is 2% after the
birth of one affected child. The recurrence risk is increased after the
birth of two affected individuals, presumably because the proportion
of germ cells that carry the mutation is higher.43 This information may
be mentioned in the results letter. If parental mosaicism can be
demonstrated in the father, the referring clinician could be encouraged
to request a sperm sample from the father to clarify the risk.
When the referring physician is not a clinical geneticist, it is
recommended that the patient be referred to a clinical genetics centre
for counselling. Referral to OI centres for therapy can be proposed if
available.
Not ﬁnding a causative variant in COL1A1 and COL1A2 genes in an
affected index case. If no causative variant is detected in the COL1A1
and COL1A2 genes after gDNA analysis and screening for large gene
deletions (eg, MLPA), an interim report can be made with the
recommendation for review of the original patient diagnosis (detailed
clinical information, eg, with use of the clinical checklist, radiographs,
contact with the referring physician (see Supplementary Appendix
Table 1)). This review of the clinical diagnosis should involve a
clinician with expertise in diagnosis and classiﬁcation of OI. The
Table 3b Prenatal and preimplantation genetic diagnosis for OI
Source Product Methods
CVS gDNA Direct sequencing
Mutation scanning (HRM/QPCR)
Deletion/duplication testing (MLPA)
Protein (Pro)collagen type I electrophoresis
Amniocytes gDNA Direct sequencing
Mutation scanning (HRM/QPCR)
Deletion/duplication testing (MLPA)
Blastocysts gDNA Sequencing of known familial mutations
Table 3a Postnatal diagnostics for OI
Source Product Methods Comments
Blood (preferred) gDNA Direct sequencing
Mutation scanning (HRM/QPCR)
Deletion/duplication testing
(MLPA)
Blood spots gDNA Direct sequencing Very low yield
Saliva or buccal
swabs
gDNA Direct sequencing High yield of
DNA possible
Mutation scanning (HRM/QPCR)
Deletion/duplication testing
(MLPA)
Fibroblasts gDNA Direct sequencing
Mutation scanning (HRM/QPCR)
Deletion/duplication esting (MLPA)a
mRNA/cDNA Sequencing for splice-site errors
Protein (Pro)collagen type I electrophoresis
Abbreviation: HRM, high-resolution melting.
aPerforming MLPA with DNA extracted from ﬁbroblasts leads to unclear results in certain cases.
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additional OI genes and cDNA and protein analysis of type I
(pro)collagen. If applicable, a new request for additional testing
should be sent by the referring physician to the laboratory. Laboratories
that do not offer analysis of the recessive genes should suggest further
analysis in another laboratory.
In the case of doubtful pathogenicity of the identiﬁed variant, the
‘Practice guidelines for the Interpretation and Reporting of Unclassi-
ﬁed Variants (UV’s) in Clinical Molecular Genetics’ (http://www.
cmgs.org/BPGs/pdfs%20current%20bpgs/UV%20GUIDELINES%20
ratiﬁed.pdf) should be applied. If the genetic testing procedure has
identiﬁed an unclassiﬁed variant as the only sequence change, this
should be reported as such. However, the report should clearly state
that the clinical signiﬁcance of the variant is unknown and that its
identiﬁcation does not provide an explanation for the clinical pheno-
type of the patient.
Finding causative variants in the CRTAP, LEPRE1, PPIB, FKBP10,
SERPINF1, SERPINH1, PLOD2, SP7 genes in an affected index case. The
ﬁnal report should state that causative variants have been detected. It is
necessary to investigate the carrier status of the parents and siblings in
order to determine whether a variant is causative. Testing of relatives at
risk may be offered in conjunction with appropriate counselling. Such
testing might be useful for prenatal diagnosis.
Finding one causative variant in the CRTAP, LEPRE1, PPIB, FKBP10,
SERPINF1, SERPINH1, PLOD2, SP7 genes in an affected index
case. When one causative recessive variant has been detected, it
cannot be excluded that a second causative variant has been missed,
for example when it concerns a deep intronic variant. Dependent on
the laboratory, a second interim report can be made indicating the
desirability for cDNA and protein analysis of type I (pro)collagen in
the case of one causative variant in the CRTAP, LEPRE1 or PPIB genes.
When these additional tests are not informative or cannot be per-
formed in the laboratory, the ﬁnal report should state that it is not
possible to conﬁrm the clinical diagnosis OI by biochemical and/or
molecular testing.
Not ﬁnding causative variants in the CRTAP, LEPRE1, PPIB, FKBP10,
SERPINF1, SERPINH1, PLOD2, SP7 genes in an affected index
case. In the case of doubtful pathogenicity of the identiﬁed variants,
the same procedure as described above for the COL1A1 and COL1A2
genes should be followed. In the case where no causative variants in
the genes involved in recessive OI have been found, the ﬁnal report
should state that it is not possible to conﬁrm the clinical diagnosis OI
by biochemical and/or molecular testing.
Not ﬁnding causative variant(s) in the genes known for autosomal
dominant and autosomal recessive OI: type I (pro)collagen electropho-
resis. Reports of these studies are necessarily more descriptive than
the DNA-based results. They should list the types of genetic alterations
that could not be identiﬁed. When low production or post-transla-
tional over-modiﬁcation of type I (pro)collagen is observed, the
diagnosis of OI can be conﬁrmed and in the case of over-modiﬁcation
of type I (pro)collagen, prenatal diagnosis on chorionic villus cells is
possible. In reports concerning cells and samples with no molecular
and/or biochemical diagnosis of OI, it should be stated that it is not
possible to conﬁrm the clinical diagnosis OI.
Prenatal or preimplantation genetic diagnosis
Prenatal or preimplantation genetic diagnosis with the intention of
terminating a pregnancy or not selecting embryos carrying the
causative variant(s) is possible in the case of identiﬁcation of known
disease-causing variant(s). This service should only be offered in a
clinical genetics service and must be accompanied by appropriate
genetic counselling. Requests for prenatal or preimplantation diag-
nosis should always be referred and announced in advance to a clinical
genetics service. In addition, the original result letter of the laboratory
that identiﬁed the causative variant should accompany the request.
CONCLUSIONS
Best practice guidelines have been established for the molecular
genetic diagnosis of OI. The most noteworthy issue is that molecular
analysis of the COL1A1/2 genes is recommended as the starting point
in the diagnostic ﬂow as opposed to protein analysis. It is to be
expected that molecular genetic testing in OI will only gain in
importance as new OI-genes are discovered and with the development
of new technologies. However, in certain selected cases protein analysis
will remain important.
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APPENDIX
Textbox 1
Interpretation of variants in the COL1A1 and COL1A2 genes.
COL1A1 and COL1A2 genes
1. Causative variants – considerations speciﬁc for the ﬁbrillar collagen genes:
The following variants are likely to have pathological consequences for the protein function:
a. Substitution of the glycine residue of every Gly-X-Y triplet repeat within the triple-helical region of the a1(I)- and a2(I)-collagen chains.
b. Sequence variants in consensus acceptor and donor splice sites (positions +1, +2,  1,  2) will lead to splicing errors of the mRNA, but the outcome cannot be
predicted without cDNA analysis, with the exception of  1G4A acceptor-site splicing variants in the triple-helical region of the a1(I) collagen chains which result in a
frameshift, nonsense-mediated mRNA decay and a null-allele.  1G4A splicing variants of exon 6 of the COL1A1 gene, results in skipping of exon 6, whereas for the
COL1A2 gene this results in use of a cryptic splice site in the exon and an in-frame deletion of 15 bases. Both are associated with EDS arthrochalasis type.
c. Nonsense mutations or deletions and insertions that result in interruption of the reading frame, nonsense-mediated mRNA decay and a null-allele.
d. In-frame deletions and insertions that lengthen or shorten the a-chains.
e. Other variants* with experimental evidence (published or own data) of their impairment of the protein’s function.
*Variants also should be checked against existing entries in the Osteogenesis Imperfecta Variant Database16,17 (https://oi.gene.le.ac.uk), which can be used for corroboration.
However, it should be recognized that the data in the database are not warranted to be accurate or ﬁt for any particular purpose.
2. Unclassiﬁed variants (UV)
a. All other sequence variants must be considered as ‘unclassiﬁed’ until segregation within the family has been investigated and/or functional evidence becomes available.
b. It is strongly recommended that intronic nucleotide substitutions other than splice-site mutations affecting the  1,  2 or +1, +2 intronic nucleotide positions be
examined by cDNA-analysis to determine their splicing outcome.
c. It is strongly recommended that UVs be further investigated by in silico analysis (eg, PolyPhen-2, SIFT, Human Splicing Finder software, and so on). Of note: the new
version of Polyphen classiﬁes almost all glycine substitutions as benign or tolerated.
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Interpretation of variants in the CRTAP, FKBP10, LEPRE1, PLOD2,
PPIB, SERPINF1, SERPINH1 and SP7 genes.
CRTAP, FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, SERPINH1 and SP7
1. Causative variants
The following variants are likely to have pathological consequences for the protein function:
a. Sequence variants in consensus acceptor and donor splice sites that will lead to splicing errors of the mRNA.
b. Nonsense mutations or deletions and insertions that result in interruption of the reading frame, nonsense-mediated mRNA decay and a null-allele.
c. Most in frame deletions and insertions that lengthen or shorten the protein.
d. See 1e in Textbox 1
2. Unclassiﬁed variants
See Textbox 1.
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